{"schema_version":"1","generated_at":"2026-11-08T09:32:19.061Z","data_as_of":null,"url":"https://www.findmykol.com/kol/david-pugatch","json_url":"https://www.findmykol.com/kol/david-pugatch/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"david-pugatch","name":"David Pugatch","credential":"MD","specialty":"Pediatric Infectious Diseases","specialty_raw":"Pediatric Infectious Diseases","therapeutic_area":"Infectious Disease","therapeutic_areas":["Infectious Disease"],"institution":"Protagonist Therapeutics","institution_url":"https://www.findmykol.com/institution/protagonist-therapeutics","city":"Madera","state":"CA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1245285147","openalex":"A5010324654"},"summary":"David Pugatch is an Infectious Disease physician affiliated with Protagonist Therapeutics. OpenAlex indexes 69 publications with 2,386 citations (h-index 26); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Infectious Disease"]},"scholarship":{"works_count":69,"cited_by_count":2386,"h_index":26,"latest_activity_year":2021,"source":"works"},"trials":{"count":1,"shown":3,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT02442258","title":"Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function","phase":"PHASE1","status":"COMPLETED","role":"Overall official","sponsor":"AbbVie","source_url":"https://clinicaltrials.gov/study/NCT02442258","trial_url":"https://www.findmykol.com/trial/NCT02442258"},{"nct":"NCT02296905","title":"Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function","phase":"PHASE1","status":"COMPLETED","role":"Overall official","sponsor":"AbbVie","source_url":"https://clinicaltrials.gov/study/NCT02296905","trial_url":"https://www.findmykol.com/trial/NCT02296905"},{"nct":"NCT01286740","title":"Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR","phase":"PHASE2","status":"COMPLETED","role":"Overall official","sponsor":"Gilead Sciences","source_url":"https://clinicaltrials.gov/study/NCT01286740","trial_url":"https://www.findmykol.com/trial/NCT01286740"}],"source":"trials"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis","year":2021,"journal":"Gastroenterology","source_url":"https://doi.org/10.1053/j.gastro.2021.08.045","status":"verified"},{"title":"Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials","year":2019,"journal":"Liver International","source_url":"https://doi.org/10.1111/liv.14266","status":"verified"},{"title":"Drug‐Drug Interactions of Tacrolimus or Cyclosporine With Glecaprevir and Pibrentasvir in Healthy Subjects","year":2019,"journal":"Clinical Pharmacology in Drug Development","source_url":"https://doi.org/10.1002/cpdd.671","status":"verified"},{"title":"799 – Efficacy of Upadacitinib As an Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis, with Or Without Previous Treatment Failure of Biologic Therapy: Data from the Dose-Ranging Phase 2B Study U-Achieve","year":2019,"journal":"Gastroenterology","source_url":"https://doi.org/10.1016/s0016-5085(19)37216-6","status":"verified"},{"title":"Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects","year":2018,"journal":"Antimicrobial Agents and Chemotherapy","source_url":"https://doi.org/10.1128/aac.01990-17","status":"verified"}],"source":"works"},"similar":[{"name":"Thomas Walsh","slug":"thomas-walsh","institution":"Cornell University","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/thomas-walsh","json_url":"https://www.findmykol.com/kol/thomas-walsh/profile.json"},{"name":"Douglas Richman","slug":"douglas-richman","institution":"University of California San Diego","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/douglas-richman","json_url":"https://www.findmykol.com/kol/douglas-richman/profile.json"},{"name":"Henry Masur","slug":"henry-masur","institution":"National Institutes of Health","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/henry-masur","json_url":"https://www.findmykol.com/kol/henry-masur/profile.json"},{"name":"Vance Fowler","slug":"vance-fowler","institution":"Duke University","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/vance-fowler","json_url":"https://www.findmykol.com/kol/vance-fowler/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"}},"methodology_url":"https://www.findmykol.com/about#methodology"}